Management of severe or rare immune-related adverse events in the context of an interdisciplinary tumor board

Management of severe or rare immune-related adverse events in the context of an interdisciplinary tumor board - IrTOX trial

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037940

Enrollment

100

Registered

2025-09-19

Start date

2024-01-10

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune-related adverse events

Interventions

Group 1: Patients who are registered for the tumorboard for immune-related adverse events are evaluated retrospectively for type of IrAE, diagnostics, treatment, severity and duration, type of cancer,

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients with suspected immune-related adverse events due to a malignant disease - Signed consent form

Exclusion criteria

Exclusion criteria: Age < 18 years

Design outcomes

Primary

Measure	Time frame
Optimizing the management of patients with immune-related adverse events	—

Secondary

Measure	Time frame
Overall and progression-free survival in patients with immune-related adverse events, IrAE severity, response to IrAE therapy, steroid tapering, second line immunosuppressant, infections	—

Countries

Germany

Contacts

Public ContactRobert Zeiser

Universitätsklinikum Freiburg

robert.zeiser@uniklinik-freiburg.de+4976127034580

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026